Uncontrolled growth of cells is caused due to mutation to genes in cancer. The uncontrolled grown cell again moves from one part of body to another through blood and lymph system. There are different types of cancer out of which Leukemia is one. Cancer which is formed in blood tissues is called as Leukemia. Leukemia occurs due to the uncontrolled growth of with blood cells in the bone marrow. White blood cells are the protectors of our body from different infections. Leukemia is the most common type of cancer that is caused among adult males because they are not diagnosed at proper time. The most familiar syndrome of Leukemia is weight loss, night sweats, fever, frequent infections and enlarged liver size. There are different types of Leukemia out of which are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia.
How Big is the Global Leukemia Therapeutics Market?
The Global Leukemia Therapeutic Market is expected to be around US$ 14.60 Billion by 2028 at a CAGR of 4% in the given forecast period.
The major driving factors of Global Leukemia Therapeutic Market are as follows:
The restraining factors of Global Leukemia Therapeutic Market are as follows:
The Global Leukemia Therapeutic Market is segmented on the lines of its therapy, type and regional. Based on therapy segmentation it covers Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy, other. Based on type segmentation it covers Chronic leukemia, acute leukemia, others. The Global Leukemia Therapeutic Market on geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographic market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.
This report provides:
1) An overview of the global market for Global Leukemia Therapeutic Market and related technologies.
2) Analyses of global market trends, with data from 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2028.
3) Identifications of new market opportunities and targeted promotional plans for Global Leukemia Therapeutic Market.
4) Discussion of research and development, and the demand for new products and new applications.
5) Comprehensive company profiles of major players in the industry.
REPORT SCOPE:
The scope of the report includes a detailed study of global and regional markets on Global Leukemia Therapeutic Market with the reasons given for variations in the growth of the industry in certain regions.
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc. Genzyme Corporation, AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.
The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.
The Global Leukemia Therapeutic Market has been segmented as below:
By Therapy Analysis:
By Type Analysis:
By Regional Analysis:
Reasons to Buy this Report:
1) Obtain the most up to date information available on all Global Leukemia Therapeutic Market.
2) Identify growth segments and opportunities in the industry.
3) Facilitate decision making on the basis of strong historic and forecast of Global Leukemia Therapeutic Market data.
4) Assess your competitor’s refining portfolio and its evolution.
Customization:
We can offer you custom research reports as per client’s special requirements.
Below are our New Reports :-
1 INTRODUCTION
1.1 Key Take Aways
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size
1.5.2 Market Share
1.5.3 Key Data Points From Secondary Sources
1.5.4 Key Data Points From Primary Sources
2 EXECUTIVE SUMMARY
2.1 OVERVIEW OF THE MARKET
3 MARKET OVERVIEW
3.1 DEFINING LEUKEMIA
3.1.1 DIAGNOSIS
3.1.1.1 Biopsy and bone marrow aspiration
3.1.1.2 Complete blood count (CBC) and differential
3.1.1.3 Philadelphia chromosome’s presence
3.1.1.4 Spinal tap (lumbar puncture) and cerebrospinal fluid (CSF) analysis
3.1.1.5 Immunophenotyping or phenotyping by flow cytometry
3.1.1.6 Polymerase chain reaction (PCR)
3.1.2 LEUKEMIA PREVALENCE
3.1.3 INCIDENCE & MORTALITY
3.2 TYPES OF LEUKEMIA
3.2.1 BASED ON DEVELOPMENTAL & PROGRESSION RATE
3.2.1.1 Chronic leukemia
3.2.1.2 Acute leukemia
3.2.2 BASED ON BONE MARROW CELLS AFFECTED
3.2.2.1 Lymphocytic (lymphoblastic) leukemia
3.2.2.2 Myelogenous (also called myeloid) leukemia
3.2.3 BASED ON DEVELOPMENT/PROGRESSION RATE & TYPE OF BONE MARROW CELLS AFFECTED
3.2.3.1 Acute Lymphocytic Leukemia (ALL)
3.2.3.2 Chronic Lymphocytic Leukemia (CLL)
3.2.3.2.1 B-cell CLL
3.2.3.2.2 T-cell CLL
3.2.3.2.3 Hairy cell leukemia
3.2.3.2.4 Large granular lymphocytic leukemia
3.2.3.3 Acute Myeloid Leukemia (AML)
3.2.3.4 Chronic Myeloid Leukemia (CML)
3.3 STAGES/PHASES OF LEUKEMIA
3.3.1 ACUTE LYMPHOCYTIC LEUKEMIA
3.3.1.1 Childhood ALL
3.3.1.1.1 Standard (low) risk
3.3.1.1.2 High risk
3.3.1.1.3 Recurrent
3.3.1.2 Adult ALL
3.3.1.2.1 Untreated adult ALL
3.3.1.2.2 Adult ALL in remission
3.3.1.2.3 Recurrent adult ALL
3.3.2 CHRONIC LYMPHOCYTIC LEUKEMIA
3.3.2.1 Stage 0
3.3.2.2 Stage I
3.3.2.3 Stage II
3.3.2.4 Stage III
3.3.2.5 Stage IV
3.3.3 ACUTE MYELOID LEUKEMIA
3.3.3.1 Childhood AML
3.3.3.2 Adult AML
3.3.4 CHRONIC MYELOGENOUS LEUKEMIA
3.3.4.1 Chronic stage
3.3.4.2 Accelerated stage
3.3.4.3 Blastic stage
3.3.4.4 Relapse
3.4 MARKET STRUCTURE
3.4.1.1 Key therapies
3.4.1.1.1 Chemotherapy
3.4.1.1.2 Stem cell/bone marrow transplant
3.4.1.1.3 Radiation therapy
4 LEUKEMIA MARKET DYNAMICS
4.1 MARKET OVERVIEW
4.2 BURNING ISSUES
4.3 WINNING IMPERATIVES
4.3.1 BMS STRATEGY ON PRODUCT EDUCATION THROUGH ONLINE SERVICES
4.4 MARKET DYNAMICS
4.4.1 MARKET DRIVERS
4.4.1.1 Innovative therapies to drive the market for leukemia
4.4.1.2 Oncology is the largest therapeutic market with high unmet needs
4.4.1.3 Off-label prescribing drives market growth.
4.4.2 MARKET RESTRAINTS
4.4.2.1 Adverse events of treatment
4.4.2.2 Low production capability for efficient drugs
4.4.3 MARKET OPPORTUNITIES
4.4.3.1 Limited players in the market
4.4.3.2 Growing older male population
4.4.3.3 Leukemia’s underserved patient populations offer potential for market growth
5 LEUKEMIA PRODUCT MARKET
5.1 MARKET OVERVIEW
5.1.1 GLEEVEC
5.1.2 SPRYCEL
5.1.3 TASIGNA
5.1.4 CAMPATH/MABCAMPATH
5.1.5 TREANDA
5.1.6 ARZERRA
5.1.7 FLUDARA
5.1.8 FCR REGIMEN
5.1.9 FC REGIMEN
5.1.10 HYPER-CVAD
5.1.11 CALGB 8811 REGIMEN
5.1.12 LINKER REGIMEN
5.1.13 NUCLEOSIDE METABOLIC INHIBITORS (CLOLAR + ARRANON)
5.1.14 ONCASPAR
5.1.15 DAUNORUBICIN + CYTARABINE (FOR INDUCTION)
5.1.16 CYTARABINE (FOR RELAPSE)
5.1.17 DAUNORUBICIN + CYTARABINE (FOR ELDERLY)
5.1.18 VCD REGIMEN (APL)
5.1.19 AVD REGIMEN (APL)
6 LEUKEMIA DRUG PIPELINE (PHASE III)
6.1 PIPELINE DRUGS
6.1.1 BOSUTINIB
6.1.2 OMAPRO
6.1.3 GA101/RG7159
6.1.4 VIDAZA
6.1.5 DACOGEN
6.1.6 MIDOSTAURIN
6.1.7 VOSAROXIN
6.1.8 QUIZARTINIB
6.1.9 GRASPA
6.1.10 MARQIBO
7 GEOGRAPHIC ANALYSIS
7.1 U.S.
7.2 CANADA
7.3 U.K.
7.4 GERMANY
7.5 FRANCE
7.6 ITALY
7.7 SPAIN
7.8 JAPAN
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
The Global Leukemia Therapeutic Market has been segmented as below:
By Therapy Analysis:
By Type Analysis:
By Regional Analysis:
SUBSCRIBE TO OUR NEWSLETTERS
